Status:
UNKNOWN
Ranibizumab for Myopic Neovascularization
Lead Sponsor:
Instituto de Olhos de Goiania
Conditions:
Myopic Choroidal Neovascularization
Eligibility:
All Genders
21-65 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate the clinical results of anti-VEGF intra-vitreal injections (IVT) in CNV secondary to pathologic myopia (PM-CNV).
Detailed Description
Twenty consecutive patients (30 eyes) with subfoveal PM-CNV, 9 of whom had been unsuccessfully treated with Visudyne PDT, were treated with IVT of 0.5mg ranibizumab. ETDRS best corrected visual acuity...
Eligibility Criteria
Inclusion
- Myopic and CNVM
Exclusion
- Patients with poor compliance
- Patients with uncontrolled diabetes and hypertension or any other medical condition that increase the risk of complications like recent history of Stroke or myocardial infraction (\< one year). (Physician clearance was obtained for all patients).
- Age related macular degeneration with Juxtafoveal and Subfoveal CNVM: Recurrent CNVM following PDT and TTT with IVTA. Patient who could not afford PDT, Macugen or Lucentis which is FDA approved.
- Patients who had undergone major surgery 28 days before, were excluded from the study and it was also suspended prior to elective surgery.
- Refractory macular oedema due to vein occlusion, Pseudophakia, Clinically significant macular oedema (CSME) etc. that affects vision and does not respond adequately to usual treatment methods.
- Proliferative diabetic retinopathy, non-resolving vitreous haemorrhage with PDR.
- Idiopathic CNVM, Inflammatory CNVM and other conditions associated with CNVM.
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2014
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01246089
Start Date
July 1 2009
End Date
November 1 2014
Last Update
January 1 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto de Olhos de Goiania
Goiânia, Goiás, Brazil, 74120-050